Class Action Suit Against Capricor Therapeutics: Investors Urged to Act

Class Action Lawsuit Against Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a biotechnology company noted for its drug candidate deramiocel, is currently embroiled in a legal battle following allegations of securities law violations. The law firm DJS Law Group has alerted investors about a class action lawsuit against the company, focusing on its correspondence and public statements made between October 9, 2024, and July 10, 2025. The case is calling attention to specific claims made by Capricor regarding its path to FDA approval for deramiocel, which allegedly misrepresented the company’s actual progress and results.

Background of the Lawsuit

According to the filed complaint, Capricor is accused of making false and misleading statements about its clinical trials, particularly its Phase 2 HOPE-2 trial. During the class period, Capricor claimed that the development of deramiocel was progressing positively, which led investors to believe that the company was successfully navigating the FDA approval process. However, the company apparently had access to adverse data from the trial, which contradicted its public announcements. This discrepancy has led to significant financial losses for shareholders who bought into the company under the belief that it was on the verge of success.

The allegations involve violations of various sections under the Securities Exchange Act of 1934, emphasizing the need for transparency and integrity from publicly traded companies. The lawsuit specifically highlights the breaches of §§10(b) and 20(a) and Rule 10b-5 as established by the U.S. Securities and Exchange Commission.

Investors Encouraged to Join the Class Action

Investors who purchased Capricor shares during the stated period are urged to contact DJS Law Group for potential participation in this class action. The law firm is set up to assist those who might want to pursue lead plaintiff status, although it is not a prerequisite for participation in any potential recovery. There is no cost or obligation for shareholders who register with the firm; they will receive continuous updates on their case status, aided by portfolio monitoring software designed to track developments.

Why Choose DJS Law Group?

DJS Law Group represents a wide array of investors, from small shareholders to some of the largest hedge funds globally. Their expertise is primarily centered on securities class actions, corporate governance, and other legal matters involving financial implications. The firm aims to deliver results through aggressive advocacy, emphasizing the importance of upholding investors' rights and maximizing returns. By supporting the class action against Capricor, DJS Law Group seeks to ensure that the voices of shareholders are heard and respected.

If you believe you've been disadvantaged due to Capricor's alleged misrepresentations, now is the time to act. Joining this class action could provide an opportunity for recovery against the company’s alleged misconduct while strengthening accountability for future corporate behaviors.

Contact Information

To learn more about this lawsuit and about joining the case, contact David J. Schwartz at DJS Law Group by calling 914-206-9742 or via email at [email protected]. As this situation unfolds, it’s crucial for affected investors to stay informed and involved.

This press release may regard attorney advertising in specific jurisdictions, so potential plaintiffs are advised to consider all aspects before proceeding.